THOUSAND OAKS, Calif. - Biotechnology firm Amgen (NASDAQ:AMGN) has announced a second quarter dividend of $2.25 per share for 2024, scheduled for payment on June 7 to shareholders on record by May 17. This declaration follows Amgen's pattern of sharing profits with its investors, reflecting the company's financial health and commitment to shareholder returns.
Amgen, a pioneer in the biotechnology industry since 1980, has established itself as a key player in the field of human therapeutics. The company's focus on serious illnesses with high unmet medical needs has led to the development of a range of innovative treatments. Amgen's strategic approach combines advanced human genetics and a deep understanding of human biology to address complex diseases.
As an independent biotech company, Amgen has made significant strides in reaching patients worldwide and continues to develop a promising pipeline of potential medicines. The company's influence is recognized by its inclusion in the Dow Jones Industrial Average and the Nasdaq-100 index, indicative of its standing in the financial markets.
In the previous year, Amgen has been acknowledged for its workplace environment and sustainability efforts, receiving accolades from Newsweek, USA Today, and TIME. These recognitions highlight Amgen's broader commitments beyond its core mission of patient care.
It is important to note that this press release contains forward-looking statements based on current expectations and beliefs, which are subject to risks and uncertainties. These statements include projections and estimates regarding the company's financial performance, product marketing, and business operations.
As with all forward-looking statements, actual results may vary, and the company does not commit to updating any such statements in the future.
The information provided is based on a press release statement from Amgen, which outlines the dividend announcement and offers insight into the company's operations and achievements. The dividend declaration is a key piece of information for investors and market watchers, reflecting Amgen's financial practices and its ability to generate shareholder value through consistent returns.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.